Investors & Media
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.
To learn more about Ionis follow us on twitter @ionispharma.
Recent Press ReleasesMore >>
Upcoming EventsMore >>
|Summary Toggle 04/09/19 12:50 pm EDT||
New York, NY
|Summary Toggle 06/15/19 12:15 pm CEST - 1:45 pm CEST||
ESHG 2019 Corporate Satellite Event Bridging The Gap: Translating Genomic Discovery Into Human Therapeutics
Bridging The Gap: Translating Genomic Discovery Into Human Therapeutics
Cvent link: http://www.cvent.com/d/x6q9l1
European Society of Human Genetics Annual Conference
Copyright West LLC. Minimum 15 minutes delayed.